MeiraGTx buys back gene therapy from J&J; Storm brings in $56M Series Cnews2026-04-16T15:21:54+00:00April 16th, 2026|Endpoints News|
Biogen filing reveals Apellis deal details; Telix raises $600Mnews2026-04-15T15:15:34+00:00April 15th, 2026|Endpoints News|
Harbinger raises $100M; Astellas to close Seattle sitenews2026-04-14T14:52:35+00:00April 14th, 2026|Endpoints News|
Neomorph raises $100M for molecular glues; Spyre’s ulcerative colitis datanews2026-04-13T15:19:10+00:00April 13th, 2026|Endpoints News|
Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera optionnews2026-04-10T15:13:51+00:00April 10th, 2026|Endpoints News|
FDA lifts MacroGenics hold; Oxford and Bristol Myers team upnews2026-04-09T15:10:37+00:00April 9th, 2026|Endpoints News|
Merck adjusts its vaccine supply deal in China; Soleno withdraws EU applicationnews2026-04-08T15:24:21+00:00April 8th, 2026|Endpoints News|
Novo launches high-dose Wegovy in the US; Evotec pressured to list its US unitnews2026-04-07T15:14:50+00:00April 7th, 2026|Endpoints News|
Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trialnews2026-04-06T14:37:53+00:00April 6th, 2026|Endpoints News|
Lipocine’s postpartum depression drug fails; AstraZeneca claims liver cancer winnews2026-04-02T14:42:52+00:00April 2nd, 2026|Endpoints News|
